Merck-Medco switching patients from Zestoretic to Prinizide, APhA's Knowlton tells FDA.
MERCK-MEDCO SWITCHING PATIENTS FROM ZESTORETIC TO PRINIZIDE, according to an example of prescription drug switch programs detailed by American Pharmaceutical Association President Calvin Knowlton at FDA's public hearing on promotions to managed care Oct. 19-20. Knowlton said pharmacists have been objecting to a "prescription change authorization notification" sent by Medco's PAID Prescriptions to switch patients from Zeneca's antihypertensive/diuretic Zestoretic to Merck's Prinizide.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth